Quanterix Corporation reported financial results for the third quarter of fiscal 2026, ending September 30, 2026. The company announced total revenue of $35.0 million for the quarter, representing a 6.3% increase compared to the previous quarter. This figure is a decrease from the prior year's third quarter, which saw total revenues of $40.2 million.
For the nine months ended September 30, 2026, the company reported total revenues of $104.3 million, down from $95.0 million in the same period the prior year. The company reported a net loss of $21.6 million for the third quarter, a 35.6% improvement compared to the prior year's net loss of $33.5 million. The company ended the quarter with $80.7 million in cash, cash equivalents, marketable securities, and restricted cash.
On the business operations front, Quanterix highlighted several developments. The company completed building its senior management team, naming Jim Gute as Chief Commercial Officer in August and Dr. Yuri Fesko as Chief Medical Officer in September. The company also announced expanded insurance coverage for its LucentAD Complete blood test in Florida, effective November 1, 2026, covering traditional Medicaid members and state employees.
Quanterix also entered new commercial partnerships with Sherman Abrams Lab in New York and TruPath in Mississippi. Additionally, the company received regulatory approvals in China for its HD-X and SR-X instruments and testing kits for four biomarkers through a partnership with Innovita Biological Technology Co.
Regarding its 2026 business outlook, Quanterix narrowed its expectations for total revenues to a range of $142.0 million to $146.0 million. The company continues to expect adjusted gross margins (non-GAAP) to be in a range of 48% to 50%. Quanterix now expects to end 2026 with a cash balance of approximately $70.0 million and no debt.
